HONG KONG–(BUSINESS WIRE)–Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today iss…
Uncategorized
Young ophthalmologists should not ignore ergonomics
ORLANDO — Younger ophthalmologists need to hear the message of proper ergonomics as early as possible, according to a speaker at the American Academy of Ophthalmology meeting.Robert Swan, MD, of SUNY Upstate Medical University, said that people usually…
Uncategorized
GLP-1s, fenofibrates reduce risk for diabetic macular edema
GLP-1 receptor agonists and fenofibrate medications significantly reduced the risk for developing diabetic macular edema, according to a study published in Ophthalmology Retina.Conversely, patients on calcium channel blockers were more likely to develo…
Uncategorized
FDA approves Yuflyma for two expanded indications
The FDA approved expanded indications of Yuflyma and its unbranded version to treat hidradenitis suppurativa in adolescents aged 12 years and older and uveitis in children aged 2 years and older, according to a press release.Yuflyma (adalimumab-aaty, C…
Uncategorized
FDA approves Epioxa for keratoconus
The FDA approved Epioxa for the treatment of keratoconus, Glaukos announced in a press release.“We’re proud to announce an extraordinary milestone for keratoconus patients with the approval of Epioxa,” Thomas Burns, Glaukos chairman and CEO, told Heali…
Science Corp.’s PRIMA BCI Implant Restores Functional Central Vision to Patients with Geographic Atrophy Caused By Age-Related Macular Degeneration, a Leading Cause of Blindness, The New England Journal of Medicine Reports
ALAMEDA, Calif.–(BUSINESS WIRE)–The New England Journal of Medicine (NEJM) today published a peer-reviewed original paper with the results of a landmark clinical trial demonstrating the efficacy of Science Corporation’s PRIMA brain-computer interface…